Acquisition reflects that regulatory-grade real-world evidence will play increasing role in drug discovery, development, commercialization and reimbursement.
Roche says its planned purchase of cancer data specialist Flatiron Health Inc. will help the Swiss group progress its own pipeline while helping to design the use of real-world evidence (RWE) to set new industry standards for oncology research and development.
The acquisition, announced Feb. 15, stems from an existing partnership between the two companies,with Roche already holding a 12.6% stake...
While there may be the beginnings of a turnaround in biopharma capital markets, gains in the cell and gene therapy space may lag the broader sector recovery, noted speakers at ARM’s Cell and Gene Meeting on the Mesa.
The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.
With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.
The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.
The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.
The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.
Raising UK drug prices and offering lower list prices only to those US patients who are under- or uninsured were the industry’s initially cosmetic answers to the administration’s most favored nation drug pricing challenge. Then Pfizer stepped in.
